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Abstract 
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            Adenovirus vectors have demonstrated many of the characteristics necessary to be 
successfully used as a carrier in a vaccine delivery system.  Adenovirus is a good choice 
for a vaccine carrier because it generates vigorous T and B cell responses to its transgene 
products.   Although current vaccination strategies using this vector have had some 
success, its use has been constrained by the presence of pre-existing immunity to human 
serotypes in about 50% of the population.  Recently, it has been demonstrated that the 
induction of these adenovirus-specific neutralizing antibodies that reduce efficacy of 
initial treatment and booster immunizations does not apply to oral delivery. 
 vii
Adenovirus is a good candidate for oral vaccine delivery because it is capable of 
inducing antibody responses against an encoded transgene product at mucosal surfaces, 
which may result in complete systemic and mucosal immunity.  Nevertheless, there are 
some limitations associated with the oral delivery of protein, peptide, and virus-based 
vaccines.  Virus-based vaccines are sensitive to the low pH and presence of proteases in 
the gut limiting their activity and cellular uptake is also hindered by the rapid transit time 
of compounds through the intestine.  
In general, there are two primary strategies for enhancing mucosal immunity: 
mucosal adjuvants and encapsulation in microparticles.  Although several groups have 
successfully encapsulated adenovirus in polymeric formulations, it has been found that 
the encapsulation process drastically reduces viral function.  However, the best 
performance has been reported with formulations containing poly(lactide-co-glycolide) 
(PLGA). 
Thus, the primary objective of this study was to optimize the encapsulation 
process of a recombinant adenovirus vector in PLGA microspheres to maximize virus 
stability and promote intestinal gene transfer.  Production parameters were systematically 
adjusted to find the best formulation for virus release and stability.  Optimization of the 
production process increased viral release from 7 to 15 days and resulted in a 200-fold 
increase in the total number of infectious virus particles released compared to the original 
formulation. 
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Introduction 
 
1. Current Status of Gene Therapy 
As of January 2007, there are over 1260 gene therapy clinical trials that 
have taken place in more than 28 countries worldwide, with 85 approved in 2006 
alone, according to statistics published online by The Journal of Gene Medicine 
(Wiley Database, 2007).  The gene therapy products tested in these studies are 
designed to battle a variety of illnesses including cancer, vascular disease, 
monogenic disease, and infectious disease. Although the majority of these 
studies are still in phase I testing (67%), there are 40 trials at or beyond the 
phase II / III level of the clinical trial process (Wiley Database, 2007).    
The drugs tested in these studies include a wide range of delivery vehicles 
including viruses, naked DNA, plasmid DNA, liposomes, and RNA transfer.  
Adenovirus vectors are involved in more studies (26%) than any other type of 
vector used in all clinical trials and are the vectors used in the only gene therapy 
product approved by a governmental regulatory agency (Wiley Database 2007; 
Majhen et al., 2006).  Gendicine, which uses a recombinant human adenovirus-
p53 for tumor suppression, was developed by Shenzhen SiBiono GeneTech for 
the treatment of squamous cell carcinoma of the head and neck and was 
approved by the State Food and Drug Administration of China in October 2003 
(Peng, 2005).       
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2. The Structure and Function of Adenoviruses 
 Adenovirus was discovered by W.P. Rowe while isolating human adenoid 
cells.  Since then, adenovirus has been found in over 100 different mammalian 
species consisting of 87 serotypes, 50 of which are proven to infect and replicate 
in an assortment of human cells from tissues of the liver, respiratory tract, urinary 
bladder, eye, and gastrointestinal tract (Rux et al., 1999; Giamcomo et al., 2003; 
Verma et al., 2005).  Of the six subgroups of adenoviruses classified, Ad2 and 
Ad5 from subgroup C are the most widely studied for clinical application because 
of their nominal pathogenesis and typically mild disease states (Vecil et al., 
2003).   
 Adenoviruses are iscosahedral shaped particles with an outer diameter 
between 70 and 90 nm.  The outer protein shell, called the capsid, is composed 
of 240 hexons (polypeptide II), 12 penton bases (polypeptide (III), and knob fiber 
(polypeptide IV) located at each of the vertices.  Encased within the capsid is a 
36 kb segment of linear double-stranded DNA which contains an inverted 
terminal repeat at both ends providing the cis-acting signal essential for viral 
replication (Majhen et al., 2006; Rux et al., 1999; Vecil et al., 2003; Volpers et al., 
2004). 
 The adenovirus genome is divided into three different transcriptional unit 
categories according to there time of expression during the viral replication 
process.  The early transcriptional units include E1A, E1B, E2, E3, and E4.  E1A, 
E1B, and E4 are involved in manipulating the cell to facilitate a favorable 
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environment for virus replication, aiding survival of infected cells, and controlling 
the cell cycle.  The E2 segment is responsible for DNA replication and E3 helps 
in undermining the host’s immune response against the virus.  After viral 
replication, the four intermediate and single late transcriptional units are 
expressed and provide for the structure of the capsid proteins (Giamcomo et al., 
2003; Majhen et al., 2006). 
 The entry of adenovirus into the cell takes place in four steps: receptor 
interaction, endosomal lysis, microtubule movement, and nuclear entry.  The 
fiber knob and penton base of the virus interact and bind with the cell’s primary 
receptor CAR (coxsackie and adenovirus receptor) and secondary receptors, 
integrins αvβ3 and αvβ5.  These three receptors are found on many cell types 
including epithelial, muscle, fibroblast, and neural cells.  Within 5 minutes of 
binding, adenovirus can be found inside the endosome allowing the penton 
bases to breakdown the endosomal membranes facilitating endosomal escape.  
The hexons of the virus maneuver the particle along the microtubules towards 
the cell’s nucleus.  Along the way, the viral capsid proteins surrounding the DNA 
are degraded and released allowing the DNA entry into the nucleus to begin the 
processes of gene expression and virus replication (Majhen et al., 2006; Seth, 
1999; Volpers et al., 2004). 
 After integrating with the nucleus, early virus proteins are expressed and 
force the cell to enter S-phase.  During S-phase, the virus’s DNA is synthesized 
using the host cells natural functions.  Self-induced cell death is attenuated with 
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the expression of products produced by E1A preventing both p53-independent 
and dependent apoptosis.  As the infection progresses, other genes encoding the 
structure of the virus are expressed until the cell produces approximately 104 to 
105 particles.  When the cell dies, the virus is spread to other nearby cells to 
produce more progeny infectious virions (Branton, 1999; Volpers et al., 2004). 
 
3. Adenovirus Vectors for Gene Therapy 
 Adenovirus vectors, usually serotype 2 or 5, are specifically designed to 
minimize pathogenicity yet efficiently infect cells across a wide range of tissues.  
First generation vectors deleted the E1 portion of the virus to inhibit virus 
replication and replaced it with a transgene up to 4.9 kb.  Since the E1 section of 
the vector was removed, the virus had to be propagated in trans by using a cell 
line containing the E1 gene product such as the human kidney 293 cell line.   
Further development of this vector also removed the E3 segment allowing a 
transgene capacity of up to 8.3 kb; however these vectors still displayed high 
toxicity and immunogenicity (Katayose et al., 1999; Verma et al., 2005; Volpers 
et al., 2004). 
 To decrease the immune response generated by the first generation 
adenovirus vectors and increase the loading capacity, second generation vectors 
deleted or inactivated the E2 and / or E4 segments.  However, these vectors still 
produced high immunogenicity, which led to the development of “gutted” vectors.  
These third generation vectors allow incorporation of transgenes up to 36 kb 
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because they do not carry any viral sequences except the inverted terminal 
repeats and packaging signal.  The drawback associated with gutless adenovirus 
vectors is that they are much more difficult to produce requiring a helper-
dependent vector to provide the E1 functions in trans (Verma et al., 2005; 
Volpers et al., 2004). 
 
4. Toxicity and Immunogenicity of Adenovirus Vectors 
 The host immune response associated with many gene delivery systems, 
including both non-viral and viral vectors, has been one of the major impediments 
facing current gene therapy treatment.  Therefore, understanding and limiting this 
response is crucial to the development of viable gene therapy strategies. 
Recombinant adenoviral vectors have been one of the most widely studied 
vectors in gene therapy research because of their efficiency in transducing a 
wide variety of cells. However, adenovirus vectors are known to stimulate both 
the innate and adaptive immune system when given in vivo (Murvue, 2004).   
The strength of the host’s immune response to adenovirus vectors is 
greatly influenced not only by the dose of particles administered, but also by the 
route of administration, which inherently can alter localized uptake (Zhou et al., 
2004).  Intravenous adenoviral administration results mostly in hepatic and 
splenic uptake, while other routes of administration result in more localized viral 
distribution patterns.   Rats dosed with adenovirus by other routes of 
administration, such as intraperitoneal, subcutaneous, and mucosal, show limited 
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signs of toxicity compared to animals dosed intravenously (Morrissey et al., 
2002). 
The initial innate response triggered against the adenovirus capsid takes 
place within hours and is characterized by the induction of cytokines and 
chemokines including tumor necrosis factor α, interleukin-6, interleukin-1β, 
interferon γ, macrophage inflammatory protein 2 (MIP-2), MIP-1α, and MIP-1β.  
These agents act to localize the infection and recruit effector cells such as 
macrophages, monocytes, natural killer cells, and granulocytes to the site for 
additional support. This first phase immune response takes place within 24 hours 
and is produced by all generations of adenovirus vectors, including those 
inactivated, indicating that viral genes do not provoke the innate response 
(Murvue, 2004).    
 The second phase of the immune response occurs 4 to 5 days after 
administration and is mounted by the adaptive immune system.  This response is 
characterized by helper CD4+ T cells activated by MHC I complexes on the 
surface of antigen presenting cells and the formation of cytotoxic CD8+ T cells by 
the binding of CD8+ cells to the MHC I complex. CD4+ T cells release interleukin-
2, interleukin-4, and interferon-γ to enhance the development of the immune 
response against the virus. Cytotoxic CD8+ T cells are produced specifically 
against the virus itself or the transgene product (Kaplan, 1999).  This response 
against the virus is not observed with gutless or inactivated vectors indicating the 
need for gene transcription for significant adaptive recognition (Murvue, 2004).   
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5. Adenovirus Vectors as Vaccines 
Despite the presence of over 400 discrete viruses with the ability to infect 
humans, vaccines are available for less than 20 of these pathogens (Xiang et al., 
2003).  Historically, traditional means of vaccination involved the use of 
inactivated pathogens introduced systemically to provide immunity. This 
approach has limited ability in protecting against diseases such as HIV, herpes, 
or Ebola and has yet to produce any approved vaccines against parasitic or 
fungal human diseases (Souza et al., 2005). With recent advances in molecular 
biology, many approaches using DNA and recombinant viruses as vaccine 
carriers are under investigation and have demonstrated some success in a 
number of preclinical and clinical trials (Bangari et al., 2006).  One of the most 
successful vehicles in this field thus far has been the adenovirus vector.  
Previous use of adenovirus vectors by the US military has demonstrated 
safety and efficacy using this virus as a vaccine for respiratory disease (Souza et 
al., 2005).   Adenovirus vectors are a good choice for a vaccine carrier because it 
generates vigorous T and B cell responses to its transgene products (Kobinger et 
al., 2005).  They have also demonstrated the ability to generate strong immunity 
using many different routes of administration including subcutaneous, 
intravenous, intramuscular, and mucosal (Bangari et al., 2006).    
The majority of adenovirus vector vaccine work has centered on human 
adenovirus serotype 5 (HAd5).  HAd5 is currently undergoing pre-clinical trials as 
a vaccine vector against Ebola virus, HIV-1, malaria, anthrax, and severe acute 
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respiratory syndrome.  Non-human primates in these studies were protected 
against lethal challenge after immunization with the HAd5 expressing specific 
transgenes (Bangari et al., 2006; Brave et al., 2006).  Although current 
vaccination strategies using this vector have had some success, its use has been 
constrained by the presence of pre-existing immunity to human serotypes in 
about 50% of the population (Nwanegbo et al., 2004; Xiang et al., 2003).  
Recently, it has been demonstrated that the induction of these adenovirus-
specific neutralizing antibodies that reduce efficacy of initial treatment and 
booster immunizations does not apply to oral delivery (Xiang et al., 2003).   
 
6. Oral Administration of Adenovirus Vectors 
Adenovirus is a good candidate for oral vaccine delivery because it is 
capable of inducing antibody responses against an encoded transgene product 
at mucosal surfaces, which may result in both complete systemic and mucosal 
immunity (Boyer et al. 2005).  Mucosal immunization is highly desirable for 
vaccination because many infectious pathogens naturally access the host 
through mucosal membranes.  This non-invasive means of delivery increases 
practicality and compliance by reducing injection site reactions and the risk of 
disease transmission through biohazzardous waste, which can occur through the 
more commonly used intramuscular method of administration. 
Although the oral route is generally considered the pinnacle route of 
administration of many common medicinal agents, there are limitations 
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associated with the oral delivery of vaccines.  Protein and virus-based vaccines 
are sensitive to the low pH and presence of proteases in the gut limiting their 
activity in vivo.  Cellular uptake is also hindered by the rapid transit time of 
compounds through the intestine and the limited ability of intestinal epithelial cells 
to readily absorb large molecules (Delgado et al., 1999; Singh et al., 1998).   
In general, there are two primary strategies for enhancing mucosal 
immunity: mucosal adjuvants and encapsulation in microparticles (Lameiro et al., 
2006).  Although several groups have successfully encapsulated adenovirus 
vectors into polymeric formulations, it has been found that the encapsulation 
process drastically reduces viral function (Barrio et al., 2004; Beer et al., 1998; 
Davison et al., 1997).  However, the best performance has been reported with 
poly(lactide-co-glycolide) (PLGA) based preparations (Lameiro et al., 2006). 
 
7. PLGA for Microsphere Production 
PLGA is an FDA approved, amorphous, non-toxic, biodegradable polymer 
(molecular weight between 10 to 100 kDa) composed of lactide and glycolide 
monomers of varying ratios (50:50 to 100:0) linked together by ester bonds.  
Degradation of PLGA occurs by hydrolytic cleavage of the ester bonds in 
aqueous fluids producing lactic and glycolic acids which are metabolized into 
carbon dioxide and water (Tamber et al., 2005).  The degradation rate of the 
polymer can be adjusted by changing the monomer ratio, the molecular weight, 
or hydrophilicity of the polymer (Kang et al., 2001).  In recent years, the use of 
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this polymer to entrap antigens into polymeric microspheres for controlled 
release drug delivery systems has been extensively studied.   
 The most common technique to encapsulate antigens into polymeric 
microspheres is solvent evaporation.  This method involves dissolving the 
polymer in an organic solvent and dispersing the antigen by homogenization to 
form a water-in-oil emulsion.  This primary emulsion is further dispersed in a 
larger aqueous volume forming a water-in-oil-in-water (W / O / W) emulsion 
producing the antigen loaded microspheres.  Many factors such as polymeric 
properties, organic solvents, stirring rates, emulsion stabilizers, and 
concentrations have been found to significantly alter antigen stability during 
encapsulation (Beer et al., 1997; Singh et al., 1998; Tamber et al.; 2005). 
 Dichloromethane and ethyl acetate are the two most commonly used 
organic solvents for solvent evaporation with PLGA.  Some important factors that 
must be considered when choosing the organic solvent to use for this process 
include toxicity, volatility, and aqueous solubility.  Dichloromethane has a median 
lethal dose (LD50) in rats of 5.62 g / kg, a boiling point of 40°C, and an aqueous 
solubility of 2% v / v.  Although ethyl acetate demonstrates improved tolerance 
(LD50 of 1.6 g / kg in rat) and has been used orally in humans to improve flavor in 
foods, it has a much higher boiling point of 77°C and increased water solubility of 
10% v / v (Sah et al., 1997; Singh et al., 1998). The higher boiling point increases 
the amount of residual solvent in the system after the evaporation time under 
vacuum.  This is especially important for protein or virus-based systems which 
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would be sensitive to the elevated temperatures required to remove all of the 
solvent. 
 Microsphere size can be influenced by both the concentration of polymer 
used to form the primary emulsion and the stirring rate used to form the emulsion 
(Singh et al., 1998).   Particle size is of particular importance for oral vaccine 
delivery with PLGA because microspheres less than 10 µm have been found to 
be naturally taken up by the Peyer’s patches, where they are presented to 
antigen presenting cells (Desai et al., 1997; Shakweh et al., 2005).  Considering 
that the polymer concentration is directly proportional to particle size, lower 
polymer concentrations between 2 to 5 % are often used to achieve small 
particles sizes.  The stirring rate is inversely proportional to particle size with 
faster rates producing a decrease in microsphere diameter; however the 
increased stirring rates can denature protein and virus-based drugs due to the 
shear stress on the compounds (Stivaktakis et al., 2004). 
 Another important factor to consider during microsphere formation is the 
choice and concentration of stabilizer used in both the primary and secondary 
emulsion steps.  The concentration of stabilizers found in most microshere 
preparations usually range from 0.1% to 10% with higher concentrations yielding 
increased loading levels and more regular size distributions. Polyvinyl alcohol 
(PVA) is the most commonly used stabilizer in W / O / W emulsions because it 
demonstrates high solubility in water and has a low toxicity (Singh et al., 1998).       
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8.  Summary of Objectives 
 Because of the many factors influencing the stability and release of 
adenovirus vectors from PLGA microsphere formulations, we propose that 
optimizing each parameter in the emulsion process will enhance virus stability 
and maximize release over time.  An initial preparation was prepared with 1 ml of 
5 x 1012 virus particles (vp) / ml of a first generation adenovirus vector expressing 
the beta-galactosidase transgene using a PLGA concentration of 100 mg / ml, a 
polymer lactide to glycolide ratio of 50:50, dichloromethane, and 1% w / v PVA.  
This microsphere preparation released 1.44 x 106 infectious virus particles (ivp) 
over a period of 10 days resulting in over a 4-log drop from the number of 
infectious virus particles incorporated into the system.  Therefore, the first 
objective of this study is to increase the total number of infectious virus particles 
released over time from the system.   
 The second objective of this study is to investigate the basis for this loss in 
infectious virus released after encapsulation, as well as, determine the influence 
of microsphere storage conditions on virus release.  Studies will be performed to 
determine the stability of adenovirus upon exposure to organic solvents and 
release buffer. The influence of different storage conditions, length of storage, 
and drying microspheres after collection will also be investigated. 
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Materials and Methods 
 
1.  Chemicals and Reagents 
PLGA polymers with monomer ratios of 50:50, 65:35, and 75:25, polyvinyl 
alcohol (PVA), polyvinyl pyrrolidone (PVP), polyethyleneimine (PEI), phosphate 
buffered saline (PBS), pepsin, Hanks’ Balanced Salt solution (HBBS), non 
essential amino acid solution (NEAA), sodium pyruvate, sodium caprate, sodium 
laurate, sodium taurocholate, linoleic acid, ethylene glycol tetraacetic acid 
(EGTA), squalene, DEAE dextran, Tween® 80, and Span® 85 were purchased 
from Sigma Chemicals (St. Louis, MO).   Ethyl acetate, dichloromethane, L-
glutamine, sucrose, sodium chloride, sodium bicarbonate, and sodium citrate 
were obtained from EMD Chemicals (Gibbstown, NJ).  X-gal was ordered from 
Gold Biotechnology Inc. (St. Louis, MO). Dulbecco’s Modified Eagle’s Medium 
(DMEM, Cellgro, Mediatech, Herndon, VA) containing 10% fetal bovine serum 
(FBS, BioWhittaker, Walkersville, MD) and 1% penicillin-streptomycin (PCN, 100 
U/ml) was used for all cell culture work unless otherwise stated. 
 
2.  Adenovirus Purification.  
 A replication deficient adenovirus vector expressing the E. coli beta-
galactosidase transgene (AdlacZ) was amplified in human embryonic kidney 
293T cells and purified as previously described (Callahan et al., 2006).  Briefly, 
we purified the viral vector by cesium chloride density ultracentrifugation.  After 
the first centrifugation, bands were collected and layered on a second gradient 
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for further purification.  After final centrifugation, bands were collected and 
desalted on an Econo-Pac 10DG disposable chromatography column (BioRad, 
Hercules, CA).  The viral fractions were collected and the concentrations were 
adjusted to a final concentration of 5 x 1012 virus particles (vp) / ml after 
determination by UV spectrophotometric analysis at 260nm (Beckman Du 530 
UV/Vis, Fullerton, CA).  We calculated the final number of vp / ml by the following 
equation: 
 
Virus Concentration (vp/ml) =  (Absorbance at 260nm) x dilution x 1.1 x 1012  
(Maizel et al., 1968).   
 
Endotoxin tests were performed on all reagents used for adenovirus 
preparations with a QCL-1000 Chromogenic LAL Endpoint assay kit (Cambrex 
Bioscience, Walkersville, MD). Final adenovirus preparations used contained 
less than 0.2 E.U./ml.  The sterility of all adenovirus preps used in this study was 
tested in accordance with the guidelines established for biotechnology-derived 
drug substances by the U.S. Pharmacopeia (2005).  
 
Replication Competent Adenovirus Detection Assay (RCA) bioassay was 
performed on adenoviral preparations used in this study.  Using the method of 
Murakami et al., approximately one RCA event was detected for every 3 x 1012 
virus particles tested (Murakami et al., 2002). 
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3. Microencapsulation of Virus – General Protocol 
PLGA polymers (100 mg/ml) of varying monomer ratios were dissolved in 
5 ml of organic solvent, either dichloromethane or ethyl acetate, to form a 
polymer solution.  A primary emulsion was prepared by homogenizing 1 ml of 
AdlacZ (5 x 1012 vp / ml) in the polymer solution for 2 minutes.  The resulting 
emulsion was then added to a 10 ml aqueous solution containing 1% (w/v) PVA, 
or other substituted surfactants at varying concentrations, and homogenized for 
an additional 2 minutes.  The consequent water-in-oil-in-water (W/O/W) emulsion 
was added to a 100 ml aqueous solution containing 0.1% (w/v) PVA and stirred 
under vacuum for 2.5 hours to facilitate solvent evaporation.  The formed 
microspheres were then collected by gentle centrifugation, washed three times 
with PBS, air-dried, weighed and either directly resuspended in 1 ml of PBS for in 
vitro release studies at 37°C,  or stored at 24°C, 4°C, -20°C, or -80°C for stability 
release studies. 
 
 
 
 Figure 1: Microsphere Production Process.  A primary emulsion is formed by 
rapidly stirring a high concentration of adenovirus with a solution of PLGA 
previously dissolved by homogenization in organic solvent.  The primary 
emulsion is placed into an aqueous phase containing PVA to facilitate the 
formation of a W/O/W emulsion.  The emulsion is transferred to a large aqueous 
volume containing a surfactant and stirred under vacuum for 2.5 hours to 
enhance solvent evaporation and allow microsphere hardening. Microspheres 
are then washed, collected, and air-dried.  After drying, the microspheres can be 
either resuspended for release or stored for later use.  
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4. Modifications of General Protocol for Optimization 
The general protocol formulation used for encapsulation was 
systematically adjusted to determine the influence of each parameter on AdlacZ 
stability and overall release profile.  Parameters subject to optimization were: 
a.) Polymer lactide:glycolide ratio 
 • 75 :25 
 • 65 :35 
 • 50 :50 
 b.) Polymer concentration in organic solvent 
  • 50 mg/ml 
  • 100 mg/ml 
 c.) Virus concentration in infectious virus particles (ivp) / ml 
  • 8.7 x 1010 ivp / ml 
  • 1.74 x 1011 ivp /ml 
d.) Organic solvent 
  • Dichloromethane 
  • Ethyl acetate 
 e.) Osmotic balance of emulsion 
  • Aqueous solution - 1% PVA  
• Aqueous solution - 1% PVA / 2% NaHCO3 /10% sucrose 
 
5. Microsphere Release Sampling Procedure 
After suspension in PBS for release studies, samples were collected at 2 
and 4 hours after suspension and then daily until virus release was no longer 
detected.  At each sampling time point, microspheres were gently centrifuged to 
the bottom of the tube and the entire volume of supernatant was removed.  After 
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removal, the microspheres were resuspended in 1 ml of PBS and returned to 
37°C until the next sampling time.  This process was repeated for every time 
point during the study. 
 
6.  Determination of Infectious Viral Particles 
Supernatants from microspheres suspended in PBS for in vitro release 
studies were collected at various time points and frozen at -80°C in a 1:1 dilution 
with DMEM supplemented with 2% FBS and 1% PCN (2% media).  Aliquots from 
frozen supernatants were serially diluted in 2% media and added to 293 cell 
monolayers for 2 hours at 37°C.  After this time, 1ml of DMEM (10% FBS, 1% 
PCN) was added to each well and infection continued for 24 hours.  Cells were 
stained histochemically with 5-bromo-4-chloro-3-indoxyl-beta-D-
galactopyranoside (X-gal) for beta-galactosidase expression (Croyle et al., 
2002.).  Cells expressing the transgene were counted and the number of 
infectious virus particles released was determined by the following formula: 
(Average number of positive cells) x dilution x 845* x 10 = Number of ivp / ml 
*This number is a magnification factor valid for 12-well culture plates using a 20x 
objective.  Each aliquot from microsphere supernatant was assayed three 
separate times in three different wells.  The averages of these three 
concentrations were used for the number of infectious virus particles released 
per time point.  
 
 19
7. X-gal Staining of Cells 
Infected cells were washed with PBS, fixed with 0.5% glutaraldehyde for 
10 minutes, and washed with a PBS solution of 1mM MgCl2.  The infected cells 
were subsequently stained with X-gal by incubating in the dark for at least 4 
hours at 37°C. After the reaction, the stain was removed and the cells were 
washed with PBS to facilitate the counting of blue-stained positive cells.  Ten 
fields per well were counted to determine the number of infectious virus particles 
released. 
 
8. Simulated Gastric Fluid Release Studies 
Simulated gastric fluid (SGF) containing 7 ml of 1N HCL, 2 g NaCl, and 
3.2 g pepsin / L was prepared and used in vitro to simulate microsphere 
exposure to the the gut.  A known quantity (0.45 g) of microspheres was exposed 
to SGF for 1 hour at 37°C and samples were taken at 15, 30, and 60 minutes.  
After the final sampling time, microspheres were collected by gentle 
centrifugation and the SGF was removed.  The microspheres were washed three 
times with 10 ml of PBS and resuspended in buffer for release at 37°C according 
to the previously stated microsphere release sampling procedure.  Washes were 
kept and analyzed for virus presence using the same method. 
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9. Particle Size 
Particle size of microsphere preparations was determined at 0, 1, 7, and 
14 days after suspension in buffer from release studies.  An aliquot of 
microspheres were removed from the tube and particle size was measured by 
dynamic light scattering (Protein Solutions DynaPro, Wyatt Technlogy Co.). 
 
10. Stability of Virus  
Stability of AdlacZ was assessed to determine the effect of exposure to 
organic solvent during the encapsulation process and to incubation in the release 
buffer following release at 37°C.  To determine stability of the virus in organic 
solvent, AdlacZ was diluted to 1 x 1011 vp / ml in either dichloromethane or ethyl 
acetate.  Samples were collected at 0, 1, 2, 5, 10, 20, 30, and 60 minutes.  To 
assess the stability of the virus in release buffer, AdlacZ was diluted in PBS and 
samples were collected at various time points.  All samples were assayed 
immediately for quantifying the change in the number of ivp / ml. 
 
11. Effect of Storage Conditions on Microsphere Release 
After air-drying, collection, and weighing, equal quantities of microspheres 
were either resuspended immediately for release, stored short-term, or stored 
long-term.  Short-term stability was performed on microspheres stored at 24°C 
and 4°C for 1 day and -20°C and -80°C for 1 week.  Long-term stability was 
performed on microspheres stored at -80°C for 1 month.  When the specified 
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time was reached, microspheres were removed from storage and suspended in 
PBS for in vitro release according to the microsphere release sampling 
procedure. 
 
13. Validation of Sample Titer and Microsphere Prep Reproducibility  
 To determine the variability of intra-sample titers, four random samples 
were chosen from three identically prepared microsphere batches. Three aliquots 
from each sample were tittered in different wells of 293 cells and X-gal stained.  
The average number of infectious virus particles was assessed for each 
individual well.  The variability of titers from each sample was reported as the 
relative standard deviation (RSD), where RSD equals the standard deviation 
divided by the means of the three samples.  
For the determination of inter-prep variability of infectious virus particles 
released at specific time points, the means of three preps at each corresponding 
sampling time was assessed.  The variability of infectious virus particles released 
at each time point for all three preps were assessed by the RSD.  The variability 
in the total number of infectious virus particles released was determined by 
randomly picking four time points from three different preps and reporting the 
RSD.  
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Results 
 
1.  Inter-prep Variability of Release from Single Batch of Microspheres  
For determination of inter-prep variability, three separate batches of 
microspheres were prepared following the same protocol on three different days.  
A virus concentration of 5 x 1012 vp / ml of AdlacZ, previously frozen in 1 ml 
aliquots from the same virus preparation, was used for each microsphere 
preparation for this study.    The release profile of total infectious virus particles 
released is shown in Figure 2.  There was no significant difference in the number 
of infectious virus particles released at any time during the course of the study.  
One day after resuspension, prep 1 released 9.42 x 106 ivp, prep 2 released 9.63 
x 106 ivp, and prep 3 released 1.02 x 107 ivp.  The total number of infectious virus 
particles released by the three preps remained comparable through 11 days.  At 
that time, preps 1 and 2 both released a total of 1.1 x 107 ivp, whereas prep 3 
released 1.6 x 107 ivp.   
 Inter-prep variability of the total number of infectious virus particles 
released is shown in Table 1.  Four random time points (1, 4, and 7 days, and 
total release) were investigated for all three preparations and the RSD were 
reported.  RSD for the earliest time point chosen was 4.14%; however the RSD 
climbed to 24.87% after all three preps completed their release at 11 days.   
 
 
 
 Figure 2:  Inter-prep Release Variability.  The data are based on total release 
of infectious virus particles determined by X-gal staining of 293T cells infected 
with supernatant as described in the Material and Methods section.  Three 
microsphere batches were prepared using general protocol with dichloromethane 
as the organic solvent.  The data represent the mean ± standard error of three 
separate titers using aliquots from microsphere supernatant.  
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Table 1: Inter-prep Variability of Total Infectious Virus Particles 
Sample Time Prep #1 Prep #2 Prep #3 Mean SD RSD 
1 day 9.42x106 9.63x106 1.02x107 9.75x106 4.04x105 4.14% 
4 days 1.05x107 1.04x107 1.24x107 1.11x107 1.13x106 10.15%
7 days 1.08x107 1.04x107 1.43x107 1.18x107 2.15x106 18.13%
Total 1.10x107 1.07x107 1.63x107 1.27x107 3.15x106 24.87%
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2. Validation of Intra-sample Titers 
 Intra-sample variability was performed using 3 aliquots from microsphere 
samples at each specified time point.  Each aliquot was tested on a different well 
of 293 cells and X-gal stained for the determination of infectious virus particles 
released.  This assay was performed on three different microsphere preparations 
and the means, standard deviation (SD), and relative standard deviations (RSD) 
were calculated for each and for all three preps at each randomly chosen time 
point (Table 2).  At 4 hrs, the RSD for preps 1- 3 ranged from 5.68% to 16.79% 
with an overall RSD of 7.60%.  The 1 day release showed somewhat more 
variability with the RSD ranging from 15.23% to 21.84%.  The overall RSD for all 
three preps at 1 day was 24.34%.  At 4 days, the RSD for the individual preps 
ranged from 7.38% to 19.99% with the overall RSD equaling 20.07%. 
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Table 2: Validation of Intra-sample Titers of Infectious Virus Particles 
Sample 
Time 
Prep 
# Well 1 Well 2 Well 3 Mean SD RSD 
 1 3.47x106 3.13x106 3.17x106 3.25x106 1.85x105 5.68% 
4 hrs 2 3.38x106 3.21x106 2.66x106 3.08x106 3.77x105 12.21%
 3 3.55x106 4.98x106 4.25x106 4.26x106 7.15x105 16.79%
 All    3.53x106 2.68x105 7.60% 
 1 2.20x106 1.69x106 1.44x106 1.77x106 3.87x105 21.84%
1 day 2 1.18x106 1.26x106 9.30x105 1.12x106 1.72x105 15.23%
 3 1.32x106 1.01x106 1.52x106 1.28x106 2.57x105 20.02%
 All    1.39x106 3.39x105 24.34%
 1 1.77x105 1.44x105 1.61x105 1.60x105 1.67x104 10.41%
4 day 2 3.30x105 2.87x105 2.96x105 3.40x105 2.25x104 7.38% 
 3 6.76x105 9.30x105 1.01x106 8.72x105 1.74x105 19.99%
 All    4.45x105 8.94x104 20.07%
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3.  PLGA Monomer Ratio Influence on Virus Release 
Microsphere batches were prepared using three different lactide:glycolide 
monomer ratios (75:25, 65:35, and 50:50) to determine the influence of each on 
infectious virus particles released over time. PLGA composed of a 
lactide:glycoldie ratio of 65:35 released the highest quantity of infectious virus 
particles, 2.45 x 107 ivp, over the course of the 24 hour period following 
resuspension (Figure 3).  This value was a 23-fold increase in infectious virus 
particles released at that time point compared to that observed in microspheres 
prepared using a 50:50 polymer ratio (1.06 x 106 ivp).   This 23-fold increase in 
total infectious virus particles released was maintained throughout the remainder 
of the study.  PLGA composed of a lactide:glycolide ratio of 75:25 released 4 
times more infectious virus particles (4.36 x 106 ivp) than the 50:50 polymer ratio 
24 hours after suspension in release buffer.  Even though the total amount 
released with this ratio is less than that released by the 65:35 polymer ratio, the 
rate of release of total infectious virus particles increased over the course of the 
next four days.  The increase in rate can be observed by the 7-fold increase in 
total infectious virus particles seen at 4 days (9.2 x 106 ivp) compared to the 
50:50 polymer ratio (1.3 x 106 ivp).  The 7-fold increase in total infectious virus 
particles released was maintained throughout the remainer of the study. The 
50:50 polymer ratio released a total of 1.44 x 106 ivp over 10 days.  The 75:25 
polymer ratio released a total of 1.02 x 107 ivp over 14 days and the 65:35 ratio 
released 3.07 x 107 ivp over 12 days. 
 
 
Figure 3: Effect of Lactide:Glycolide Ratio on Active Virus Release.  The 
data are based on total release of infectious virus particles determined by X-gal 
staining of 293T cells infected with supernatant as described in the Material and 
Methods section.  Microspheres were prepared using general protocol with 
dichloromethane as the organic solvent.  The data represent the mean ± 
standard error of three separate titers using aliquots from microsphere 
supernatant.  
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4.  Influence of PLGA Concentration on Virus Release 
To determine the influence of PLGA concentration used in the 
microsphere formulation on the infectious virus particles released over time, two 
different polymer concentrations, 50 mg/ml and 100 mg/ml, were employed.  
Over the course of 24 hours following suspension in release buffer, the 
microspheres prepared with 100 mg/ml PLGA released a total of 9.47 x 106 ivp, 
over 44 times more than that released from microspheres prepared using a 50 
mg/ml concentration (2.14 x 105 ivp).  The rate of release from the 50 mg/ml 
PLGA microspheres over the following 6 days increased compared to that of the 
100 mg/ml (Figure 4).  At 7-days, a total of 6.47 x 105 ivp were released from the 
50 mg/ml PLGA, whereas 1.15 x 107 ivp were released from microspheres 
prepared with 100 mg/ml PLGA.  This 18-fold increase in total infectious virus 
particles released was observed throughout the remained of the study.  The 50 
mg/ml polymer concentration released a total of 6.52 x 105 ivp for 8 days and the 
100 mg/ml preparation resulted in 1.19 x 107 ivp released over a 10-day period.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effect of Polymer Concentration on Active Virus Release.  The 
data are based on total release of infectious virus particles determined by X-gal 
staining of 293T cells infected with supernatant as described in the Material and 
Methods section.  Microspheres were prepared using general protocol with 
dichloromethane as the organic solvent and PLGA polymer concentrations of 
either 50 mg/ml or 100 mg/ml.  The data represent the mean ± standard error of 
three separate titers using aliquots from microsphere supernatant.  
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5. Influence of the Amount of Virus Incorporated into Formulation 
Microsphere preparations were made using two different volumes of virus 
(1 ml and 2 ml at a pre-titered concentration of 8.7 x 1010 ivp / ml) to determine 
the influence of each on the number of infectious virus particles released over 
time. Therefore, a total of 8.7 x 1010 ivp was incorporated into the microsphere 
preparations containing 1 ml of virus and 1.74 x 1011 ivp into the microsphere 
batches containing 2 ml of virus.   PLGA microspheres formulated with 1 ml of 
virus released 6 times more infectious virus particles (1.02 x 107 ivp) over the 
course of the 24 hour period following resuspension than those made with twice 
the amount of virus (1.67 x 106 ivp).   At 4 days, the formulations containing 1 ml 
of virus released 1.24 x 107 ivp compared to 2.9 x 106 ivp for those prepared with 
2 ml (Figure 5).  The 1 ml virus microsphere preparations released a total of 1.65 
x 107 ivp over the course of 15 days; whereas the batches made with twice the 
amount of virus only released 2.92 x 106 ivp over an 8-day period.    
 
 
 
 
 
 
 
 Figure 5: Effect of Increasing the Amount of Virus Loaded on Active Virus 
Release. The data are based on total release of infectious virus particles 
determined by X-gal staining of 293T cells infected with supernatant as described 
in the Material and Methods section.  Microspheres were prepared using general 
protocol with dichloromethane as the organic solvent, PLGA polymer 
concentration of 100 mg/ml, and lactide:glycolide ratio of 65:35.  Microsphere 
batches containing 8.7 x 1010 ivp were prepared with 1 ml of virus and those 
containing 1.74 x 1011 ivp were prepared with 2 ml of virus. The data represent 
the mean ± standard error of three separate titers using aliquots from 
microsphere supernatant.  
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6.  Influence of Organic Solvent on Virus Release 
Microsphere preparations were prepared using two different organic 
solvents, dichloromethane and ethyl acetate, to determine the influence of each 
on the number of infectious virus particles released over time.  The total number 
of infectious virus particles released from microspheres prepared with ethyl 
acetate (2.89 x 108 ivp) was approximately 10 times more than the quantity 
released from preparations made with dichloromethane (3.08 x 107 ivp) .  This 
increase by a factor of 10 was seen at 1, 4, and 7 days following suspension in 
release buffer (Figure 6).  At 24 hours, microspheres prepared with 
dichloromethane released only 2.45 x 107 ivp compared to the 2.54 x 108 ivp 
released from the ethyl acetate preparations.  Similarly at 4 days, the 
dichloromethane and ethyl acetate batches released a total of 2.98 x 107 ivp and 
2.81 x 108 ivp, respectively.  Detectable infectious virus particles were released 
for 14 days with those prepared using ethyl acetate compared to only an 11-day 
period for the ones produced with dichloromethane as the solvent.   
 
 
 
 
 
 
 
Figure 6:  Effect of Organic Solvent on Active Virus Release.  The data are 
based on total release of infectious virus particles determined by X-gal staining of 
293T cells infected with supernatant as described in the Material and Methods 
section.  Microspheres were prepared using general protocol with either 
dichloromethane or ethyl acetate as the organic solvent, a PLGA polymer 
concentrations of 100 mg/ml, and lactide:glycolide ratio of 65:35.  The data 
represent the mean ± standard error of three separate titers using aliquots from 
microsphere supernatant.  
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7.  Comparison of Original and Optimized Formulations 
To compare the influence of optimizing all parameters investigated in the 
previous results, microspheres were prepared using the original and optimized 
formulation.  The original microsphere formulation was prepared following the 
general protocol utilizing dichloromethane as the solvent to dissolve a 100 mg / 
ml concentration of PLGA with a 50:50 lactide:glycolide ratio.  After taking into 
consideration the results of changing each parameter investigated, the optimized 
formulation consisting of ethyl acetate and a 65:35 lactide:glycolide ratio was 
also formulated.  Both the original and optimized formulations were tested with 1 
ml of 5 x 1012 vp / ml; however, the infectious virus concentration used for these 
preparations, 6.1 x 1011 ivp / ml, was larger than any previously used.  Total 
infectious virus particles released by the optimized formulation in the initial 24 
hours following resuspension was approximately 50-fold higher (3.76 x 108 ivp) 
than the active virus released from the original formulation (7.65 x 106 ivp). The 
optimized formulation continued to release detectible amounts of infectious virus 
particles for 13 days (Figure 7).  The total amount released by day 13 was 6.69 x 
108 ivp, over 63 times greater than that released over the course of 7 days by the 
original formulation (1.06 x 107 ivp).   
 
 
 
Figure 7: Effect of Optimizing Microsphere Formulation on Active Virus 
Release. The data are based on total release of infectious virus particles 
determined by X-gal staining of 293T cells infected with supernatant as described 
in the Material and Methods section.  Microspheres prepared with the original 
formulation were formulated according to the general protocol using 
dichloromethane, a PLGA polymer concentration of 100 mg/ml, and a 
lactide:glycolide ratio of 50:50.  The optimized formulation was prepared with 
ethyl acetate, a 100 mg / ml polymer concentration, and a polymer ratio of 65:35.  
1 ml of virus at a concentration of 6.1 x 1011 ivp / ml was incorporated into each 
preparation.  The data represent the mean ± standard error of three separate 
titers using aliquots from microsphere supernatant. 
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8. Influence of Sucrose and Sodium Bicarbonate on Formulation 
To further optimize the formulation, sucrose (10% w/v) was added to the 
formulation in the primary aqueous phase and the large secondary aqueous 
phase to help maintain the osmotic balance during the emulsion process 
(Srinivason et al., 2005). The sucrose would also help maintain virus activity by 
displacing some of the virus from the harmful W/O interface.  Sodium 
bicarbonate (2% w/v) was also added to the primary aqueous phase to increase 
the pH to mildly acidic conditions to help further enhance adenovirus stability 
during microsphere formation (Rexroad et al., 2006).  Total infectious virus 
particles released by the sucrose formulation in the initial 24 hours following 
resuspension was approximately 3-fold higher (1.05 x 109 ivp) than the active 
virus released from the optimized formulation (3.76 x 108 ivp). The sucrose 
formulation continued to release detectible amounts of infectious virus particles 
for 15 days, which was two days longer than the optimized formulation (Figure 8).  
The total amount released by day 15 was 2.32 x 109 ivp, over 3.5 times greater 
than that released over the course of 13 days by the optimized formulation (6.69 
x 108 ivp).   
 
 
 
 
 
 
Figure 8: Effect of Sucrose and Sodium Bicarbonate on Active Virus 
Release.  The data are based on total release of infectious virus particles 
determined by X-gal staining of 293T cells infected with supernatant as described 
in the Material and Methods section.  Microspheres in both the optimized 
formulation and the sucrose formulation were prepared according to the general 
protocol with ethyl acetate, a 100 mg / ml PLGA, a polymer ratio of 65:35, and 1 
ml of virus at 6.1 x 1011 ivp / ml. Those containing sucrose + NaHCO3 contained 
10% sucrose, 2% NaHCO3, and 1% PVA in the primary aqueous phase and 10% 
sucrose and 0.1% PVA in the large aqueous volume.  The data represent the 
mean ± standard error of three separate titers using aliquots from microsphere 
supernatant. 
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9. Representative Particle Size Distribution of Microspheres 
The particle size distribution of microspheres was taken at 0, 1, 7, and 14 
days after resuspension in release buffer (Table 3). Microspheres were 
approximately 3800 nm in size.  Adenovirus in release buffer was also detected 
with a particle size of 35 nm.  At later sampling times, the free adenovirus 
becomes aggregated as indicated by the increased particle size.  
 
 
Table 3: Representative Particle Size Distribution 
 
Time (days) 
Particle Size Distribution (nm) 
± Standard Deviation 
 
% of Population 
 
0 
35.4 
3844 
5.2 
80.6 
 
1 
72.11 ± 7.17 
3883 
8.63 
67.7 
 
7 
100.2 
3887 
8.30 
88.1 
 
14 
50.46 ± 6.92 
3586 ± 432.8 
3.96 
96.04 
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10.  Influence of Simulated Gastric Fluid on Release Profile 
To simulated microsphere exposure to the gut, microspheres were 
exposed to simulated gastric fluid (SGF) for 1 hour at 37°C, washed three times, 
and resuspended in buffer for release at 37°C.  Total virus release was 
approximately 3.4 x 106 ivp for preparations suspended in SGF for 1 hour or 
suspended directly in PBS (Figure 9).  However, 50% of the virus released from 
the microspheres incubated in SGF was obtained during incubation in SGF and 
recovered during the three washing steps (Table 4).   
 
Table 4: Active Virus Released After Exposure to SGF 
Sample Infectious Virus Particles
15 min 4.2 x 105
30 min 1.1 x 106
60 min 1.9 x 105
Wash 1.2 x 106
Total From SGF 2.91 x 106
 
 Figure 9: Effect of Simulated Gastric Fluid on Active Virus Release. The 
data are based on total release of infectious virus particles determined by X-gal 
staining of 293T cells infected with supernatant as described in the Material and 
Methods section.  Microspheres were prepared using general protocol with ethyl 
acetate, 100 mg/ml PLGA, and a ratio of 65:35.  Studies denoted by both PBS 
and SGF consisted of 0.45 g of microspheres taken from the same preparation. 
The SGF study was exposed to simulated gastric fluid for 1 hour, washed three 
times, and resuspended in PBS.  The data represent the mean ± standard error 
of three separate titers using aliquots from microsphere supernatant contained in 
SGF, washes, and PBS.  
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11.  Influence of Air-drying Microspheres on Virus Release 
Microsphere preparations were made to determine if the process air-
drying had any effect on the release profile of infectious virus particles from the 
system.  The 30 min drying process did not significantly affect the amount of 
infectious virus particles release (P > 0.05, Figure 10).  There was a slight 
difference in the early burst released between the microspheres that were 
allowed to dry and those immediately resuspended.  Within the first 4 hours, the 
microspheres that were immediately resuspended released 2.2 x 108 ivp, almost 
twice as much as that released by the dried microspheres (1.2 x 108 ivp).  
However by 2 days, both the dried and immediately resuspended preparations 
released approximately 2.6 x 108 ivp.  This comparable release profile remained 
similar for both the immediately resuspended and air-dried preparations releasing 
approximately 3 x 108 ivp over the course of 15 days. 
 
    
 
 
Figure 10: Effect of Drying Microspheres Prior to Resuspension.  The data 
are based on total release of infectious virus particles determined by X-gal 
staining of 293T cells infected with supernatant as described in the Material and 
Methods section.  Microspheres were prepared using general protocol with ethyl 
acetate, 100 mg/ml PLGA, and a ratio of 65:35.  After collection, microspheres 
were either immediately resuspended in PBS for release or air-dried in a laminar 
flow hood for 30 min prior to resuspension in PBS.  The data represent the mean 
± standard error of three separate titers using aliquots from microsphere 
supernatant. 
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12. Effect of Organic Solvent on Virus Stability 
The influence of the choice of organic solvent on the titer of infectious 
virus particles was investigated by exposing AdlacZ diluted to a concentration of 
1 x 1011 vp / ml with either dichloromethane or ethyl acetate.  Samples were 
collected for 60 min and tittered to determine changes from the initial titer of 4.1 x 
109 ivp / ml (Figure 11).  AdlacZ exposed to dichloromethane experienced a drop 
in infectious titer to 1.1 x 109 ivp / ml after only 5 min in the solvent; whereas the 
virus exposed to ethyl acetate nearly maintained its initial titer during the same 
period.  By 10 min, dichloromethane reduce the active virus concentration 17-fold 
(2.3 x 108 ivp / ml) compared to only a 10% decrease (3.7 x 109 ivp / ml) 
observed in virus exposed to ethyl acetate.  After 15 min, there was no change in 
the infectious titer observed throughout the remainder of the 60 min study.  Final 
concentrations of 1.5 x 109 ivp / ml and 6.5 x 108 ivp / ml were found at 60 min for 
the virus exposed to ethyl acetate and dichloromethane, respectively. 
 
 
 
Figure 11: Stability of Adenovirus in Organic Solvent. The data are based on 
total amount of infectious virus particles determined by X-gal staining of 293T 
cells infected with samples taken from 1 x 1011 vp /ml of  AdlacZ diluted in either 
dichloromethane or ethyl acetate. Initial titer of the dilution used for this study 
was 4.0 x 109 ivp / ml.  All samples were assayed immediately for quantifying the 
change in the number of ivp / ml. The data represent the mean ± standard error 
of three separate titers using aliquots from each sample. 
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13.  Effect of Release Buffer on Virus Stability 
To determine if the release buffer influenced the stability of AdlacZ 
released prior to sampling, 1.36 x 109 ivp / ml was placed into PBS (pH 7.4) at 
37°C for 14 days.  Loss of titer in the buffer was experienced with the most 
significant loss of 54% (7.4 x 108 ivp / ml) seen within the first 24 hours (Figure 
12).  Virus titer continued to decrease at a much slower rate over the remaining 
14 days.  Over the course of the study, virus titer dropped by 2 logs to 2.6 x 107 
ivp /ml. 
 
 
 
 
Figure 12: Stability of Adenovirus in Release Buffer.  The data are based on 
total amount of infectious virus particles determined by X-gal staining of 293T 
cells infected with samples taken from 1 x 1011 vp /ml of AdlacZ diluted in PBS 
(pH 7.4) at 37°C. Initial titer of the dilution used for this study was 1.36 x 109 ivp / 
ml.  All samples were assayed immediately for quantifying the change in the 
number of ivp / ml. The data represent the mean ± standard error of three 
separate titers using aliquots from each sample. 
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14. Effect of Storage Conditions on Microsphere Virus Release 
Microsphere preparations were made and either immediately resuspended 
in PBS for release or stored for 1 day at 24°C, 1 day at 4°C, 1 week at -20°C, 1 
week at -80°C, or 1 month at -80°C. Storage at 20°C and -80°C maintained virus 
stability for 1 week (Figure 13); however preparations stored at 24°C did not 
release any infectious virus particles after resuspension (Figure not shown).  
Storage at 4°C for 1 day reduced the number of infectious virus particles 
released by 73% and also shortened the release time from 12 to 9 days.  
Adequate stability can be maintained at -80°C for over 1 month (Figure 14). 
 
 
 
 
 
 
 
 
 
 
Figure 13: Effect of Short-term Storage on Microsphere Virus Release. 
The data are based on total release of infectious virus particles determined by X-
gal staining of 293T cells infected with supernatant as described in the Material 
and Methods section.  Microspheres were prepared using general protocol with 
ethyl acetate, 100 mg/ml PLGA, and a ratio of 65:35.  After collection, 0.4 g of 
microspheres were either immediately resuspended in PBS for release or stored 
at 4°C for 1 day, -20°C for 1 week, or -80°C for 1 week prior to resuspension.  
The data represent the mean ± standard error of three separate titers using 
aliquots from microsphere supernatant. 
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 Figure 14: Effect of Long-term Storage on Microsphere Virus Release 
The data are based on total release of infectious virus particles determined by X-
gal staining of 293T cells infected with supernatant as described in the Material 
and Methods section.  Microspheres were prepared using general protocol with 
ethyl acetate, 100 mg/ml PLGA, and a ratio of 65:35.  After collection, 0.65 g of 
microspheres were either immediately resuspended in PBS for release or stored 
at -80°C for 1 month prior to resuspension.  The data represent the mean ± 
standard error of three separate titers using aliquots from microsphere 
supernatant. 
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Discussion 
Objective 1 
 Our first objective was to increase the total number of infectious virus 
particles released over time from our original formulation which resulted in only 
1.44 x 106 ivp released over 10 days.  Typical inter-prep variability of in vitro 
release from PLGA microspheres prepared by solvent evaporation or another 
developed technique call TROMS is typically in the range of 10% to 30% (Barrio 
et al., 2003; Oster et al., 2005).  The variability in our initial microsphere 
production process also fell within this range with a RSD of 24.87% for the total 
release from three preparations.  As expected, our initial variability between the 
three batches at early time points was relatively low with a RSD of only 4.14% at 
1 day.  Much of the increase in variability over time can be attributed to the 
variability of 5.68% to 21.84% in our intra-sample titers.  Nevertheless, this figure 
fell within the range of 30% reported by Steven Bauer for this infectious virus 
particle determination assay (Bauer, 2000). 
 It is widely known that one of the major factors determining the release 
kinetics from PLGA microsheres is the lactide to glycolide ratio of the polymer 
(Kim et al., 2005). Du et al. demonstrated that a PLGA ratio of 40:60 provided a 
faster release rate in aqueous medium than other polymer ratios containing 
higher concentrations of lactide (Du et al., 2006).  From our study utilizing PLGA 
lactide to glycolide ratios of 50:50, 65:35, and 75:25, we found that the 65:35 
ratio produced the highest initial and total release of infectious virus particles 
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among the three ratios used.  Theoretically, based on the degradation rate of the 
polymer, the 50:50 PLGA should have released more infectious virus particles 
within the first 1 day of release than the other two ratios because it has the 
highest concentration of glycolide units.  However, the different polymer ratios 
can also influence the encapsulation efficiency of the antigen into the polymer 
matrix (Du et al., 2006).  We believe that the 65:35 polymer released more 
infectious virus particles because it provided a higher encapsulation efficiency of 
the virus that the other two ratios.  Another factor that must be considered in this 
instance is the molecular weight of the polymer. As molecular weight increases, 
the diffusion of the drug out of the microspheres decreases resulting in a slower 
release (Samati et al., 2006). The molecular weight of both the 50:50 and 65:35 
PLGA were 40,000 – 75,000 compared to 66,000 – 107,000 for the 75:25 ratio; 
therefore the 75:25 could have had the highest encapsulation efficiency, but its 
decreased rate of release and degradation from the higher molecular weight and 
lower glycolide unit concentration may mask this. 
 The polymer concentration utilized to form the primary emulsion also plays 
a key role in determining the encapsulating efficiency and the average particle 
size of the microspheres (Singh et al., 1998).  We determined that a PLGA 
concentration of 100 mg / ml (2% w / v) released 18 times more infectious virus 
particles compared to a lower concentration of 50 mg / ml presumably because 
of increased encapsulation efficiency. The higher concentration slightly increased 
the size of microsphere particles produced to about 3.8 µm; however, this size is 
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still small enough to be taken up by Peyer’s patches in the gut (Shakweh et al., 
2005).   
 Beer et al. previously reported that the input volume of adenovirus 
incorporated into the primary emulsion can influence the percent encapsulation 
and also the release profile of virus from the microspheres (Beer et al., 1998).  
We increased the volume of virus applied to make the primary emulsion from 1 
ml (8.7 x 1010 ivp) to 2 ml (1.74 x 1011 ivp) to determine the effect on the kinetics 
of infectious virus release.  Increasing the volume of adenovirus added to the 
system actually decreased the amount of infectious virus particles released by 
80%.  We also observed a decrease in the initial burst release profile in the 
microspheres produced with the higher concentration of adenovirus. These 
results correlate with the findings of Samati et al. that burst release decreases 
with increased drug loading (Samati et al., 2006). 
 One of the most critical parameters influencing the formation of polymeric 
microspheres is the choice of organic solvent because it can affect the rate of 
solvent removal (altering microsphere hardening), antigen stability, and 
encapsulation efficiency (Tamber et al., 2005; Singh et al., 1998). We compared 
two of the most popular solvent choices for solvent evaporation, dichloromethane 
and ethyl acetate, to determine the effect on microsphere formation and the 
infectious virus release profile.  Microspheres formed by ethyl acetate released 
10 times more infectious virus particles than those prepared using 
dichloromethane.  Based on these results, we were not able to determine 
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whether the loss was due to increased encapsulation efficiency using ethyl 
acetate or the stability of adenovirus in the solvent.  Results from a later study 
discussed in Objective II shed more light on this mater. 
 After taking all of the results into account, we developed our optimal 
formulation for improved infectious adenovirus release.  The new formulation 
resulted in an increase in total infectious virus particles 63 times more than the 
original formulation.  A total of 6.69 x 108 ivp was released over the course of 13 
days.  Our percent efficiency of this formulation was 0.11% compared to the 
0.034% reported by another improved encapsulation method (Barrio et al., 2004). 
We took this optimized formulation one step further to try to minimize the 
degradation of the virus during the encapsulation process by adding sucrose and 
sodium bicarbonate to the emulsion.  The sucrose was added in equal 
concentrations of 10% w /v to both the primary and secondary aqueous phases 
to maintain osmotic balance while forming the emulsion and to minimize the 
amount of virus coming in contact with the organic solvent at the W / O interface 
(Srinivason et al., 2005).  Sodium bicarbonate (2% w/v) was also added to the 
primary aqueous phase to increase the pH to mildly acidic conditions to help 
enhance adenovirus stability during microsphere formation (Rexroad et al., 
2006).  The infectious virus particles released with this formulation was 2.32 x 
109 ivp, 3.5 times more than our optimized formulation, improving the percent 
efficiency of infectious virus particles to 0.38%. 
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Objective II 
  The first part of our second objective was to investigate the basis 
for loss of infectious virus particles released during and after encapsulation. 
Since our best formulation released only 2.23 x 109 ivp of the 6.1 x 1011 ivp 
incorporated into the system, we looked at the effect of air-drying microspheres 
on virus release and the effect of organic solvent and release buffer on 
adenovirus itself.  Air-drying the microspheres for approximately 30 min after 
collection did not significantly affect the total infectious virus release; however, 
the initial rate of release within the first day was slower with the air-dried 
preparations due to the further hardening of the polymer shell during drying. 
 Since microsphere formulations containing ethyl acetate released on 
average 10 times more infectious virus particles than those made with 
dichloromethane, we investigated the how each solvent degraded adenovirus 
over a one hour period.  Titers of adenovirus after 10 min exposure to 
dichloromethane was 15.5 times less than when exposed to ethyl acetate, 
indicating that this was the major reason for the decrease observed in the 
microsphere release profile.   
 A similar study was conducted to determine how much active virus was 
lost in between daily sampling times after microsphere suspension in PBS 
release buffer at 37°C.  A 2-log loss in titer was experienced over the course of 
the 14 day sampling period with the most significant loss (60%) seen within the 
first 24 hours.  Since our sampling interval after the first 4 hours was conducted 
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on a daily basis, our results underestimate the total number of infectious virus 
particles released from all of our formulations.  We expect more of a loss of 
infectious virus particles than we estimated with this experiment because as the 
polymer degrades, the release buffer becomes more and more acidic, causing 
further degradation of the virus (Rexroad et al., 2006). 
 The second part of this objective was to determine the influence of storage 
conditions on the release profiles from our microsphere formulation. Storage at -
20°C and -80°C maintained virus stability for one week; however, batches stores 
at 24°C for only one day did not release any detectable infectious virus particles.  
Storage at 4°C for one day reduced the number of infectious virus particles 
released by 73% and also shortened the release time from 12 to 9 days. This 
result is not surprising since adenovirus stored in PBS at 4°C loses 10% of 
original titer in only 15 min (Croyle et al., 2001).   Adequate stability can be 
maintained at -80°C for over one month, the longest time interval we tested.   
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Conclusions 
By optimizing each parameter in the production process, we were able to 
improve the overall release profile over 218 times that released by our original 
formulation.  This method of production resulted in a formulation over 10 times 
more efficient than another improved adenovirus encapsulation method and 65 
times more efficient than our original formulation (Barrio et al., 2004). 
 Our original formulation: 
-    Input: 1.86x1011 ivp 
- Output: 1.07x107 ivp 
- Percent efficiency: 0.0058% 
-    Release time: 10 days 
 
Our optimized formulation: 
- Input: 6.1 x 1011 ivp 
- Output: 2.32 x 109 ivp 
- Percent efficiency: 0.38% 
- Release time: 14 days 
 
TROMS formulation: 
- Input: 1 x 1011 ivp 
- Output: 3.4 x 107 ivp 
- Percent efficiency: 0.034% 
- Release time: 5 days 
Despite our improvements to the encapsulation process, the release was 
not complete.  Losses in virus infectivity were the result of instability in organic 
solvent, instability during solvent evaporation, and perhaps other parameters 
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which we did not investigate in these studies herein.  Also based on our findings 
of virus instability in release buffer between sampling times, we acknowledge that 
the estimation of infectious virus particles reported throughout this paper was 
below that of the actual titer based upon infectivity assay.   
Further characterization of our microsheres is essential before taking this 
work to the next level.  In depth analysis of the particle surface morphology 
should be ascertained by scanning electron microscopy.  Transmission electron 
microscopy techniques should also be employed to provide evidence for and to 
determine an estimate of the amount of adenovirus particles remaining at the 
outer polymer surface after the emulsion process.  It is possible that the 
presence of some virus particles attached to the microshere outer surface could 
be the reason for the increased virus release in wash steps after exposure to 
simulated gastric fluid.  Testing to determine the total number of virus particles 
released, including both infectious and inactivated, should also be performed 
using Real-time PCR methods to detect a specific sequence of the adenovirus 
genome.  The amount of organic solvent remaining in the microsphere product is 
another crucial variable that needs to be determined because of the toxicity 
issues associated with ingesting ethyl acetate.    
More in vitro release profile studies could also be performed using the 
Caco-2 intestinal cell line to more accurately predict what may happen when 
implemented in vivo.  Other future directions could explore the use of mucosal 
adjuvants in combination with adenovirus and these microspheres to enhance 
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viral uptake in intestinal cells.  These methods could be aimed at disrupting gap 
junctions allowing for enhanced cellular uptake or provide for specific targeting of 
the microspheres to particular areas of gastrointestinal tract such as M cells or 
Peyer’s patches.  
  The implementation of an adenovirus expressing specific antigenic 
epitopes for vaccination against various pathogens in place of our beta-
galactosidase model would be necessary for vaccine applications.  The Ebola 
virus is one possible candidate for our vaccine delivery system. Recently, 
successful Ebola virus vaccination strategies in non-human primates have 
employed the use of adenovirus vectors expressing the Ebola glycoprotein.  After 
incorporation into our adenovirus vector and encapsulation into polymeric 
microspheres, these models could then be tested in vivo for efficacy in mice 
when faced with lethal challenge.  These studies should be performed both in the 
presence and absence of pre-existing immunity to adenovirus to characterize 
differences in the cellular and humoral immune responses against the Ebola 
glycoprotein. 
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Appendix I 
Summary of Study Parameters 
Figure Label Ratio Polymer(mg/ml) Solvent
Input 
(ivp) 
Output 
(ivp) 
3 75:25 75:25 100 DCM 2.48x1011 1.02x107
3 65:35 65:35 100 DCM 2.11x1011 3.07x107
3 50:50 50:50 100 DCM 2.11x1011 1.42x106
4 50 mg/ml 65:35 50 DCM 2.11x1011 6.52x105
4 100 mg/ml 65:35 100 DCM 1.86x1011 1.19x107
6 Ethyl Acetate 65:35 100 EA 1.86x1011 2.87x108
6 Dichloromethane 65:35 100 DCM 5.10x1011 3.07x107
10 Immediate resuspension 65:35 100 EA 1.86x10
11 2.86x108
10 Air dried then resuspended 65:35 100 EA 1.86x10
11 3.16x108
5 1 ml of virus 65:35 100 EA 8.70x1010 1.63x107
5 2 ml of virus 65:35 100 EA 1.74x1011 2.91x106
7 Original formulation 50:50 100 DCM 1.86x10
11 1.07x107
7, 8 Optimized formulation 65:35 100 EA 6.10x10
11 6.69x108
8 Sucrose + NaHCO3 65:35 100 EA 6.10x10
11 2.32x109
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